Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the safest dose of radiation that can be used. Participants in this study will be undergoing clinically scheduled procedures. In addition to the standard of care visits and treatments, there will be additional visits and assessments with radiation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka przełyku lub połączenia przełyku z żołądkiem
- •Guz powinien być możliwy do operacyjnego usunięcia zdaniem doświadczonego chirurga
- •Guz powinien być możliwy do poddania radioterapii zdaniem specjalisty
- •Dobry ogólny stan zdrowia (możliwość wykonywania codziennych czynności)
- •Prawidłowe wyniki badań krwi i funkcji narządów
- •Brak wcześniejszego leczenia chemią lub radioterapią tego nowotworu
- •Zgoda na stosowanie antykoncepcji (mężczyźni i kobiety w wieku rozrodczym)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Texas Southwestern Medical Center
Dallas, United States
Trial contact
Jennifer Knight
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.